PMSN.F Stock Overview
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Proteome Sciences plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.032 |
| 52 Week High | UK£0.094 |
| 52 Week Low | UK£0.025 |
| Beta | -0.022 |
| 1 Month Change | 0% |
| 3 Month Change | -42.15% |
| 1 Year Change | n/a |
| 3 Year Change | -67.78% |
| 5 Year Change | 23.92% |
| Change since IPO | -98.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| PMSN.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 4.1% | 1.2% |
| 1Y | n/a | 4.7% | 24.9% |
Return vs Industry: Insufficient data to determine how PMSN.F performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how PMSN.F performed against the US Market.
Price Volatility
| PMSN.F volatility | |
|---|---|
| PMSN.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PMSN.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine PMSN.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 29 | Mariola Sohngen | www.proteomics.com |
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. It offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. The company also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers, as well as bioinformatics tools.
Proteome Sciences plc Fundamentals Summary
| PMSN.F fundamental statistics | |
|---|---|
| Market cap | US$11.94m |
| Earnings (TTM) | -US$3.04m |
| Revenue (TTM) | US$6.26m |
1.9x
P/S Ratio-3.9x
P/E RatioIs PMSN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PMSN.F income statement (TTM) | |
|---|---|
| Revenue | UK£5.03m |
| Cost of Revenue | UK£3.38m |
| Gross Profit | UK£1.65m |
| Other Expenses | UK£4.09m |
| Earnings | -UK£2.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0083 |
| Gross Margin | 32.76% |
| Net Profit Margin | -48.59% |
| Debt/Equity Ratio | -366.4% |
How did PMSN.F perform over the long term?
See historical performance and comparison